Administration of cholesterol reductase to humans

Details Administration of cholesterol reductase to humans Administration of cholesterol reductase to humans

1991-11-22

1995-07-25

Wityshyn, Michael G.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Oxidoreductases

424 941, 424493, 424496, 424497, 435189, 426 56, A61K 3854

Patent

active

054360048

ABSTRACT:
Cholesterol reductase is administered to humans to convert cholesterol to coprostanol in the small intestine thus decreasing the bloodstream cholesterol level.

REFERENCES:
patent: 2697106 (1954-12-01), Shepherd et al.
patent: 2813879 (1957-11-01), Wildi et al.
patent: 2838526 (1958-06-01), Laubach
patent: 2979440 (1961-04-01), Smythe
patent: 3959540 (1976-05-01), Leiberich et al.
patent: 4001480 (1977-01-01), Shank
patent: 4009076 (1997-02-01), Green et al.
patent: 4079125 (1978-03-01), Sipos
patent: 4106991 (1978-08-01), Markussen et al.
patent: 4251387 (1981-02-01), Lim et al.
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 4362711 (1982-12-01), Cerani
patent: 4482630 (1984-11-01), Allen et al.
Lehninger "Biochemistry," Second Edition, Worth Publichsers, Inc., (1975), p. 685.
Guyton, "Textbook of Medical Physiology" Fifth Edition, W. B. Saunders Company, (1976), pp. 924 & 925.

Affiliated with

Also associated with

Rating

Administration of cholesterol reductase to humans does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Administration of cholesterol reductase to humans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of cholesterol reductase to humans will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-738209